DDrare: Database of Drug Development for Rare Diseases

Vehicle gel (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
34	Neurofibromatosis	1

13. Multiple sclerosis/Neuromyelitis optica [ 3,050 clinical trials, 2,147 drugs, (DrugBank: 348 drugs), 244 drug target genes, 228 drug target pathways]

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 3,050 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02568111 (ClinicalTrials.gov)	February 2016	1/10/2015	Brimonidine Tartrate for the Treatment of Injection Related Erythema	Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated With Sub-cutaneous Administration of Peginterferon Beta-1a (BRITE)	Relapsing-Remitting Multiple Sclerosis (RRMS)	Drug: peginterferon beta-1a;Drug: brimonidine tartrate;Drug: Vehicle Gel	Biogen	NULL	Withdrawn	18 Years	N/A	Both	0	Phase 4	NULL

34. Neurofibromatosis [ 120 clinical trials, 182 drugs, (DrugBank: 72 drugs), 84 drug target genes, 194 drug target pathways]

Searched query = "Neurofibromatosis", "NF1", "von Recklinghausen disease", "NF2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 120 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04435665 (ClinicalTrials.gov)	August 21, 2020	8/6/2020	NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)	A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas	Neurofibromatosis 1;Cutaneous Neurofibroma	Drug: NFX-179 Gel;Drug: Vehicle Gel	NFlection Therapeutics, Inc.	NULL	Recruiting	18 Years	N/A	All	48	Phase 2	United States